Hospital Pharmacy Europe

JULY 6, 2023

With Hospital Pharmacy Europe ’s inaugural Clinical Excellence in Respiratory Care event in conjunction with Hospital Healthcare Europe fast approaching, there are just a few days left to register. The post Time running out to register for MDT respiratory event appeared first on Hospital Pharmacy Europe.

Hospitals 52

Hospitals Patient Care Immunization 52

STAT

DECEMBER 18, 2023

When faced with a loved one’s progressive neurodegenerative disease, like Alzheimer’s, or your child’s rare respiratory disease, you question why researchers and resource-backed pharma cannot bring a drug to market quickly enough to help your loved ones.

FDA 138

FDA 138

PharmExec

DECEMBER 19, 2023

Pivotal trial findings show favorable clinical safety and efficacy data for mRNA-1345 in lowering the incidence of respiratory syncytial virus-associated lower respiratory tract disease.

Vaccines 52

Vaccines 52

Outsourcing Pharma

JANUARY 4, 2024

There is an urgent and unmet need to better understand the features of acute respiratory distress syndrome (ARDS), which is why a clinical research business has been selected to start a phase 2 platform clinical trial to investigate it further.

65

65

Pharmaceutical Technology

NOVEMBER 28, 2022

C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. According to the deal, C4XD is entitled to get up to $16m in pre-clinical milestone payments before the commencement of the first clinical trial. .

Immunization 105

Immunization 105

Outsourcing Pharma

JANUARY 30, 2023

The clinical trial was set up to investigate whether combining opioids with common psychotropic drugs would increase risk of respiratory depression.

FDA 92

FDA 92

Pharmaceutical Commerce

FEBRUARY 8, 2024

The FDA placed a full clinical hold on magrolimab for hematologic cancers after data showed the drug in combination with azacitidine plus Venclexta increased the risk of death related to infections and respiratory failure in patients with acute myeloid leukemia.

FDA 52

FDA 52

European Pharmaceutical Review

DECEMBER 22, 2022

It also has potential to develop vaccines for other respiratory diseases, such as flu and respiratory syncytial virus. This will include running a significant number of clinical trials in the UK. The Moderna Innovation and Technology Centre (MITC) is intended to provide access to a UK-made supply of COVID-19 jabs.

Vaccines 130

Vaccines 130

Hospital Pharmacy Europe

NOVEMBER 23, 2023

As approximately 35 million people with respiratory conditions use salbutamol inhalers worldwide, it accounts for 49% of GSK’s carbon footprint and significantly contributes to the carbon footprint of global health systems.

Hospitals 52

Hospitals 52

pharmaphorum

NOVEMBER 16, 2022

Novartis has already spun out its eyecare business Alcon, and is now considering the sale of its ophthalmology and respiratory medicines businesses as it continues a narrowing of its focus, according to media reports. The post Novartis said to be eyeing sale of ophthalmology, respiratory units appeared first on.

124

124

Pharmaceutical Technology

MARCH 21, 2023

Pre-clinical-stage biotechnology firm InvisiShield Technologies has partnered with Gladstone Institutes to develop intranasal preventatives against airborne viral infections including influenza, respiratory syncytial virus (RSV) and SARS-CoV-2.

Patient Care 115

Patient Care Immunization Vaccines 115

Pharmafile

JANUARY 9, 2024

Aiolos is a clinical-stage biopharmaceutical company with a focus on the treatment of patients with certain respiratory and inflammatory conditions. This […] The post GSK to acquire Aiolos Bio for $1bn appeared first on Pharmafile.

59

59

STAT

JANUARY 9, 2024

Founded in 2023, Aiolos is focused on developing therapies for respiratory and inflammatory conditions. It is currently developing ‘AIO-001’, a treatment for asthma that is ready to enter mid-stage clinical trials. GSK framed the purchase as a boost to its group of respiratory medicines.

Vaccines 98

Vaccines 98

Pharmaceutical Technology

APRIL 19, 2023

GSK expects that the BELLUS Health acquisition will boost its speciality medicines and respiratory pipeline. Camlipixant is being assessed in the CALM Phase III clinical development programme, with anticipated regulatory approval and launch in 2026. There are no approved medicines for the disease in the EU and the US.

97

97

Pharmaceutical Technology

FEBRUARY 19, 2024

LTX-608 is under clinical development by Talphera and currently in Phase II for Acute Respiratory Distress Syndrome.

40

40

STAT

OCTOBER 28, 2022

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned. Continue to STAT+ to read the full story…

Documentation 118

Documentation 118

Pharmaceutical Technology

JANUARY 4, 2024

Palivizumab biosimilar is under clinical development by Mabxience Holding and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections.

40

40

European Pharmaceutical Review

NOVEMBER 21, 2023

According to GSK, thirty-five million patients with respiratory conditions globally relying on its metered dose inhaler. Developing the lower carbon propellant is “complex and involves clinical and non-clinical programmes, as well as establishing new manufacturing facilities”, the company noted.

112

112

Pharma Mirror

OCTOBER 1, 2022

The Hague, Support for pharmacists to provide services to people with chronic respiratory diseases — namely asthma and chronic obstructive pulmonary disease — is available in the form of two new resources published by the International Pharmaceutical Federation (FIP) today.

52

52

European Pharmaceutical Review

JULY 4, 2023

Patients with implantable devices are more prone to biofilm-mediated infections, 3 while other infections such as skin structure infections, chronic lung diseases resulting from respiratory infections, and urinary tract infections (UTIs) can have reoccurrences despite antibiotic treatments.

79

79

Hospital Pharmacy Europe

AUGUST 23, 2023

NICE is undertaking a consultation on the provision of ‘virtual wards’ or ‘hospital at home’ for patients with an acute respiratory infection. Expanding them to support people with acute respiratory infections will give more patients the option of recovering at home.

Hospitals 52

Hospitals 52

European Pharmaceutical Review

AUGUST 17, 2023

As an alternative drug delivery method to traditional injected vaccines, live, replicating, intranasal vaccines have potential for effectively interrupting transmission of COVID-19 by inducing the development of immunity in the respiratory tract.

Vaccines 93

Vaccines Immunization 93

Pharmaceutical Technology

SEPTEMBER 5, 2022

In this period, AstraZeneca has also taken part in five oncology and respiratory disease deals, respectively. An example of AstraZeneca’s deals in the cardiovascular disease clinical landscape is its agreement with US-based Dogma Therapeutics. Another area where AstraZeneca has had significant deals has been respiratory disorders.

FDA 114

FDA Vaccines 114

Pharmaceutical Technology

JUNE 8, 2023

The European Commission (EC) has granted marketing authorisation for GSK’s respiratory syncytial virus (RSV) vaccine, Arexvy, for adults aged 60 years and above. The vaccine is indicated for active immunisation to prevent RSV-related lower respiratory tract disease (LRTD) in older adults.

Vaccines 59

Vaccines FDA 59

Hospital Pharmacy Europe

JANUARY 11, 2023

Low procalcitonin levels in patients with a lower respiratory infection (RI) are unable to identify those who might benefit from azithromycin. Antibiotics are commonly prescribed for acute respiratory infections, although most of these infections are viral in nature and for which antibiotics are ineffective. 0·25 ng/mL or less).

Hospitals 52

Hospitals 52

pharmaphorum

MARCH 11, 2021

This pharmaphorum webinar, held in association with Savana, will take place on Thursday 22 April from 16:00-17:00 BST / 17:00-18:00 CET / 10:00-11:00 EST and hear from presenters at BREATHE – the health data research hub for respiratory health, Salford Royal NHS Foundation Trust and Savana.

109

109

Hospital Pharmacy Europe

SEPTEMBER 14, 2023

Using lung progenitor cell transplantation in patients with chronic obstructive pulmonary disease (COPD) appears to improve symptoms and could lead to a cure, according to a study presented at the recent European Respiratory Society (ERS) International Congress 2023 in Milan, Italy. at baseline to 44.2% after treatment.

Hospitals 52

Hospitals 52

pharmaphorum

DECEMBER 17, 2020

Hertfordshire-based EUSA said recruitment has begun in phase 3 trial involving patients with COVID-19 previously treated with corticosteroids and other respiratory viruses associated with serious respiratory complications. Respiratory failure from ARDS is the leading cause of mortality in patients with COVID-19.

Immunization 105

Immunization 105

STAT

OCTOBER 25, 2023

As one of the largest and oldest medical device companies in the world, Medtronic has a foot in almost every clinical area. The device maker with a market valuation of nearly $100 billion sells pacemakers, spinal cord stimulators, stents, monitors. Name a device, and they probably make it.

97

97

Hospital Pharmacy Europe

AUGUST 17, 2023

The MHRA approval and NICE decisions were based on clinical data from the Phase 3 pivotal PROPEL study in which Pombiliti + Opfolda was associated with demonstrable improvements in both musculoskeletal and respiratory measures.

Hospitals 98

Hospitals 98

pharmaphorum

DECEMBER 15, 2022

However, this has led to increased transmission of other respiratory diseases and, as we’re already seeing, there are now some very real concerns about a lesser-known virus – respiratory syncytial virus, or RSV. RSV is one of the most common respiratory viruses, causing coughs and colds during the winter months. Mayo Clinic.

Mayo Clinic 68

Mayo Clinic Hospitals Vaccines 68

Pharmafile

APRIL 12, 2023

Biotechnology company Moderna has announced clinical updates detailing the expansion and advancement of its mRNA pipeline, which includes treatments for COVID-19, influenza and respiratory syncytial virus (RSV), amongst others.

Vaccines 52

Vaccines 52

Hospital Pharmacy Europe

JUNE 23, 2023

The UK should introduce routine vaccination for respiratory syncytial virus (RSV) to protect babies and older adults, the Joint Committee on Vaccination and Immunisation (JCVI) has recommended. The committee will continue to keep its advice under review as further evidence emerges and will update its advice when appropriate.’

Vaccines 98

Vaccines Hospitals 98

Outsourcing Pharma

SEPTEMBER 20, 2022

Science 37 has partnered with NuvoAir to incorporate connected devices for the remote collection of respiratory endpoints data into clinical trial designs.

52

52

European Pharmaceutical Review

OCTOBER 6, 2023

There are several benefits of the combination vaccine as a preventative measure against these respiratory conditions, according to the pharmaceutical company. “We are excited to move combination respiratory vaccines into Phase III development,” stated Stéphane Bancel, Chief Executive Officer of Moderna.

Vaccines 101

Vaccines Pharmaceutical Companies Pharmaceutical Companies 101

Hospital Pharmacy Europe

MAY 24, 2023

Patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation experience a lower annualised rate of moderate to severe disease exacerbations when dupilumab is added to standard triple therapy, the BOREAS clinical trial group found. The primary endpoint was the annualised rate of moderate or severe exacerbations of COPD.

Hospitals 98

Hospitals 98

Pharmaceutical Technology

OCTOBER 13, 2022

Oncotelic Therapeutics has received a contract from the US Biomedical Advanced Research and Development Authority (BARDA) to develop OT-101 to treat long-term effects of respiratory distress after Covid-19 infection. An antisense against TGF-?2, 2 overexpressing malignancies.

Hospitals 72

Hospitals 72